Dehydromonocrotaline (Synonyms: Monocrotaline pyrrole; MCTP; 3,8-Didehydromonocrotaline)

Cat. No.: HY-N9279: Data Sheet
SDS
Handling Instructions
FAQs
Technical Support

Dehydromonocrotaline is a mitochondrial respiratory chain complex I NADH oxidase inhibitor, with a IC₅₀ of 62.06 μM and a K_i of 8.1 μM in rats. Dehydromonocrotaline exerts non-competitive inhibitory effects by modifying cysteine thiol groups on complex I, and does not bind to the NADH-binding site. Dehydromonocrotaline dissipates mitochondrial membrane potential and reduces ATP levels. Dehydromonocrotaline can be used in studies related to hepatotoxicity, pulmonary hypertension and liver tumors.

For research use only. We do not sell to patients.

Dehydromonocrotaline Chemical Structure

CAS No. : 23291-96-5

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	Get quote	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	Get quote	Estimated Time of Arrival: December 31
Solid
1 mg	Get quote 5 - 7 weeks 4-6 weeks 6 - 8 weeks 2-3 weeks	Estimated Time of Arrival: December 31
5 mg	Get quote 5 - 7 weeks 4-6 weeks 6 - 8 weeks 2-3 weeks	Estimated Time of Arrival: December 31
10 mg	Get quote 5 - 7 weeks 4-6 weeks 6 - 8 weeks 2-3 weeks	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms

Human Endogenous Metabolite Microbial Metabolite

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Dehydromonocrotaline (100-250 μM) significantly dissipates the membrane potential of glutamate/malate-energized isolated rat liver mitochondria^[1].
Dehydromonocrotaline (100-250 μM) significantly depletes ATP levels in glutamate/malate-energized isolated rat liver mitochondria^[1].
Dehydromonocrotaline (62.06 μM) inhibits complex I NADH oxidase activity in rat liver submitochondrial particles with an IC₅₀ of 62.06 μM via non-competitive inhibition (K_i = 8.1 μM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Dehydromonocrotaline (1.5-4.5 mg/kg; single injection) induces severe pulmonary hypertension in beagles, with significant increases in pulmonary arterial pressures and vascular resistance, reduced cardiac output, and right ventricular hypertrophy at 8 weeks post-administration^[2].
Dehydromonocrotaline (formed in vivo from 10 mg/kg monocrotaline; oral gavage; single dose) contributes to the generation of a set of DHP-derived DNA adducts in rat liver with a time course of formation and removal that parallels that of riddelliine, but at significantly lower maximum levels^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	F344 (female, weanling; liver tumorigenicity model via monocrotaline administration)^[3]
Dosage:	Formed in vivo as metabolite of monocrotaline (10 mg/kg single oral dose)
Administration:	Oral gavage; single dose
Result:	Did not detect DHP-derived DNA adducts in liver DNA at 8 hours after monocrotaline dosing. Reached maximum adduct levels at 7 days after treatment, then declined over time. Dropped to levels comparable to those seen 2-3 days after dosing by 30 days after dosing. Showed maximum adduct level 8-fold lower than that in rats treated with riddelliine.

Molecular Weight

323.34

Formula

C₁₆H₂₁NO₆

CAS No.

23291-96-5

Appearance

Solid

Color

White to off-white

SMILES

O=C1O[C@@]2([H])C3=C(COC([C@](O)([C@](O)([C@H]1C)C)C)=O)C=CN3CC2

Structure Classification

Initial Source

Endogenous metabolite

Shipping

Shipping with dry ice.

Storage

-80°C, protect from light, stored under nitrogen

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (309.27 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.0927 mL	15.4636 mL	30.9272 mL
5 mM	0.6185 mL	3.0927 mL	6.1854 mL
10 mM	0.3093 mL	1.5464 mL	3.0927 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.73 mM); Suspended solution

This protocol yields a suspended solution of ≥ 2.5 mg/mL (saturation unknown). Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Data Sheet (283 KB) SDS (252 KB) Handling Instructions (2659 KB)

References

[1]. Mingatto FE, et al. Dehydromonocrotaline inhibits mitochondrial complex I. A potential mechanism accounting for hepatotoxicity of monocrotaline. Toxicon. 2007;50(5):724-730. [Content Brief]

[2]. Okada M, et al. A dehydromonocrotaline-induced pulmonary hypertension model in the beagle. J Thorac Cardiovasc Surg. 1995 Aug;110(2):546-7. [Content Brief]

[3]. Wang YP, et al. Metabolic activation of the tumorigenic pyrrolizidine alkaloid, retrorsine, leading to DNA adduct formation in vivo. Int J Environ Res Public Health. 2005;2(1):74-79. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.0927 mL	15.4636 mL	30.9272 mL	77.3180 mL
	5 mM	0.6185 mL	3.0927 mL	6.1854 mL	15.4636 mL
	10 mM	0.3093 mL	1.5464 mL	3.0927 mL	7.7318 mL
	15 mM	0.2062 mL	1.0309 mL	2.0618 mL	5.1545 mL
	20 mM	0.1546 mL	0.7732 mL	1.5464 mL	3.8659 mL
	25 mM	0.1237 mL	0.6185 mL	1.2371 mL	3.0927 mL
	30 mM	0.1031 mL	0.5155 mL	1.0309 mL	2.5773 mL
	40 mM	0.0773 mL	0.3866 mL	0.7732 mL	1.9329 mL
	50 mM	0.0619 mL	0.3093 mL	0.6185 mL	1.5464 mL
	60 mM	0.0515 mL	0.2577 mL	0.5155 mL	1.2886 mL
	80 mM	0.0387 mL	0.1933 mL	0.3866 mL	0.9665 mL
	100 mM	0.0309 mL	0.1546 mL	0.3093 mL	0.7732 mL

Dehydromonocrotaline Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Dehydromonocrotaline23291-96-5Monocrotaline pyrrole MCTP 3,8-DidehydromonocrotalineEndogenous Metabolitecysteine thiol grouphepatotoxicityratpulmonary hypertensionbeaglesrat liver mitochondriamitochondrial respiratory chain complex I NADH oxidaseglutathionepulmonary edemaDHP-derived DNA adductsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Dehydromonocrotaline (Synonyms: Monocrotaline pyrrole; MCTP; 3,8-Didehydromonocrotaline)

Dehydromonocrotaline Related Antibodies

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Endogenous Metabolite Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Dehydromonocrotaline Related Antibodies

Molarity Calculator

Dilution Calculator